Zevra Therapeutics (ZVRA) Payables (2016 - 2025)
Historic Payables for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $11.1 million.
- Zevra Therapeutics' Payables fell 5474.17% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 5474.17%. This contributed to the annual value of $25.5 million for FY2024, which is 1037.57% down from last year.
- Latest data reveals that Zevra Therapeutics reported Payables of $11.1 million as of Q3 2025, which was down 5474.17% from $15.8 million recorded in Q2 2025.
- Zevra Therapeutics' 5-year Payables high stood at $28.4 million for Q4 2023, and its period low was $2.1 million during Q3 2021.
- Its 5-year average for Payables is $12.0 million, with a median of $10.5 million in 2023.
- In the last 5 years, Zevra Therapeutics' Payables plummeted by 9703.27% in 2021 and then skyrocketed by 36041.5% in 2023.
- Zevra Therapeutics' Payables (Quarter) stood at $3.0 million in 2021, then skyrocketed by 103.06% to $6.2 million in 2022, then skyrocketed by 360.41% to $28.4 million in 2023, then fell by 10.38% to $25.5 million in 2024, then crashed by 56.51% to $11.1 million in 2025.
- Its Payables stands at $11.1 million for Q3 2025, versus $15.8 million for Q2 2025 and $17.8 million for Q1 2025.